Parabilis (PBLS) Director Craig Tendler Receives Option Award

What Happened
Craig Tendler, a director of Parabilis Medicines, was granted a derivative award on Aug 22, 2026 covering 20,294 shares (transaction code A). The reported acquisition price is $0.00, indicating a grant of a stock-based award (the filing’s footnote refers to the award as an option). No cash changed hands in this transaction.

Key Details

• Transaction date: August 22, 2026; SEC filing date: August 25, 2026.
• Transaction type/code: Award/Grant (A) of a derivative security for 20,294 shares at $0.00.
• Vesting: The award vests and becomes exercisable in 36 equal monthly installments starting Aug 22, 2026, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing notes: Footnote explicitly describes the award as an option with the monthly 36-month vesting schedule. No late-filing indicator included in the reported record.

Context
This is a compensation-related option grant to a board member, a common practice to align directors with shareholder interests. Because the award vests over three years and was not exercised or sold immediately, it does not represent an immediate buy or sell signal in the market.